Clinical Trials Logo

Filter by:
NCT ID: NCT04972266 Completed - Clinical trials for Hemodynamic Monitoring

The EU Hyprotect Registry

Start date: September 28, 2021
Phase:
Study type: Observational [Patient Registry]

European, multicenter, prospective, observational registry in patients undergoing elective major non-cardiac surgery

NCT ID: NCT04971343 Completed - HIV I Infection Clinical Trials

Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol

HIV-EU-11-18
Start date: December 4, 2019
Phase:
Study type: Observational

The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer

NCT ID: NCT04971330 Completed - HCV Clinical Trials

Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol

HCV-EU-10-18
Start date: November 4, 2019
Phase:
Study type: Observational

The objective of this study was the collection and testing of clinical samples to determine the clinical performance in terms of diagnostic accuracy measured by specificity and sensitivity of the Access anti-Hepatitis C Virus (anti-HCV) assay on the DxI 9000 Access Immunoassay Analyzer. The Design Input Document (DID) indicates performance requirements and minimum target enrollment numbers (based on those in the CTS) of blood donor, hospitalized patient and known HCV antibody (Ab) positive samples for novel anti-HCV assays. A secondary objective was to determine the false initial reactive rate (IRR) of the Access anti-HCV assay.

NCT ID: NCT04971213 Completed - Clinical trials for Cardiogenic Pulmonary Edema

HIgh Flow Versus NIV for Acute Cardiogenic PuLmonary Oedema With Acute Respiratory Failure in an ED

Start date: September 22, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare non invasive ventilation to high flow nasal cannula oxygen for the management of patients admitted with an acute respiratory failure due to an acute cardiogenic pulmonary edema.

NCT ID: NCT04970784 Completed - Clinical trials for Emergency Service, Hospital

Impact of a Dedicated Geriatric Sector on the Loss of Functional Autonomy at 1 Month for Patients Admitted to Emergencies and Non-hospitalised

URG-GERIA
Start date: June 15, 2020
Phase:
Study type: Observational

Several studies have shown that going to the emergency room is a risk factor for loss of independence in the elderly. It has been shown that the period following an emergency room visit without hospitalization is a period of vulnerability for the elderly. The functional decline, or loss of functional autonomy, of the elderly is associated with an increase in institutionalization, mortality and costs to society. Studies have highlighted the risk factors for functional decline in the elderly, such as pre-existing functional and cognitive decline, undernutrition, but no model of care has yet prevented the risk of loss of autonomy after a stay in the emergency room. A full and early geriatric assessment could prevent functional decline after the emergency room visit. The primary objective of the study is to assess the impact of a dedicated geriatric sector on the functional decline at 1 month of patients admitted to emergencies without hospitalization by comparing an intervention group (patient having benefited from the geriatric sector) and a group witness ("classic" emergency patient). The secondary objective is to evaluate the impact of this sector on the number of falls at home as well as the readmission rate within 1 month of going to the emergency room.

NCT ID: NCT04970563 Completed - Healthy Controls Clinical Trials

Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: "Proof of Concept" Study (CoviDetectionDog)-Covid-19

Start date: June 21, 2021
Phase: N/A
Study type: Interventional

The spread of the new SARS-CoV-2 virus has led to a pandemic. Described for the first time in China at the end of 2019, it causes Covid-19 disease. Its characteristics in terms of contagiousness and lethality have led countries to adapt their screening and care strategies. Early and accurate identification of people infected with SARs-CoV-2 is an essential measure to confront Covid-19 pandemic. A key aspect of Covid-19 is that diagnostic tests must be able to detect the virus in asymptomatic, pre-symptomatic and symptomatic patients. Changes in human odor, as symptoms of specific diseases, have been observed. Dogs have already been used to detect breast or lung cancer, diabetes, epilepsy or kidney disease with some success There is currently a growing body of research and previous work, though preliminary, indicating the possibility that dogs identify persons infected with Sars-Cov-2 compared to healthy persons. The purpose of this study is to determine whether trained detection dogs are able to identify asymptomatic patients infected by Sars-Cov-2. The investigators aim to validate the possibility to identify / discriminate patients with Covid-19 according to their odor by a proof of concept (with specificity and sensitivity of the detection test), i.e. new non-invasive screening method using dogs odor detection capabilities.

NCT ID: NCT04970550 Completed - Clinical trials for Rheumatoid Arthritis

Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.

VACCI-RIC
Start date: June 1, 2021
Phase:
Study type: Observational

Rheumatoid arthritis and spondyloarthritis (ankylosing spondylitis and psoriatic arthritis mainly) are chronic inflammatory rheumatism (RIC), frequently onset in young adults. The prevalence is respectively 0.3 to 0.8% and 0.4%. or about 600,000 people. The "basic" treatments (DMARDs), essential to control the progression of the disease, are classified into csDMARDs (chemical), the first of which is methotrexate, or bDMARDs (biological). These treatments are immunomodulators and there is an increased risk of severe infection under these therapies. Several vaccinations are therefore recommended by learned societies in patients receiving these treatments, in order to prevent certain infectious risks.In the current pandemic context, the vaccination of these patients against SARS-Cov2 is a major issue in their management and is recommended by the French society of rheumatology. However, many patients express doubts about this vaccination or refuse it. The factors associated with the vaccination will are not known. Better identifying them would make it possible to adapt the information to be given to our patients to promote their adherence.

NCT ID: NCT04970082 Completed - Clinical trials for Coronary Artery Stenosis

A Study to Evaluate Direct Wire Pacing (DWP) for Measuring Fractional Flow Reserve (FFR)

Start date: June 17, 2021
Phase: N/A
Study type: Interventional

This is a randomized, non-inferiority, crossover investigation comparing the Direct Wire Pacing (DWP) versus standard method to measure Fractional Flow Reserve (FFR) in subjects with FFR indications. All subjects requiring on a clinical basis a pressure wire assessment of coronary artery stenosis(es) will be eligible to take part in the study.

NCT ID: NCT04969848 Completed - Multiple Sclerosis Clinical Trials

Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device

eMSGait
Start date: August 18, 2021
Phase:
Study type: Observational

Gait alteration is frequent in MS and limitation in walking ability is a major concern in MS patients. The development of wearable device offers the opportunity to collect data during daily activity including walking.

NCT ID: NCT04968912 Completed - Sjogren's Syndrome Clinical Trials

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Start date: September 21, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.